NOVAVAX INC
10-Q, EX-27, 2000-11-13
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: NOVAVAX INC, 10-Q, 2000-11-13
Next: ENTRADA NETWORKS INC, 8-K/A, 2000-11-13



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          10,059
<SECURITIES>                                         0
<RECEIVABLES>                                      613
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                10,706
<PP&E>                                           2,551
<DEPRECIATION>                                 (1,002)
<TOTAL-ASSETS>                                  14,487
<CURRENT-LIABILITIES>                            2,027
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           200
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    14,487
<SALES>                                          1,668
<TOTAL-REVENUES>                                 1,668
<CGS>                                                0
<TOTAL-COSTS>                                    9,326
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (7,204)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (7,204)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (7,204)
<EPS-BASIC>                                     (0.38)
<EPS-DILUTED>                                   (0.38)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission